Among the study participants, 22 (25.3%) had luminal A breast cancer, 24 (27.6%) had luminal B breast cancer, 13 (14.9%) had HER‐2 positive breast cancer, and 28 (32.2%) had TNBC. Here, ERBB2 is linked to breast cancer.